New ways to image and target tumour hypoxia and its molecular responses

Ludwig J. Dubois*, Raymon Niemans, Simon J. A. van Kuijk, Kranthi M. Panth, Nanda-Kumar Parvathaneni, Sarah G. J. A. Peeters, Catharina M. L. Zegers, Nicolle H. Rekers, Marike W. van Gisbergen, Rianne Biemans, Natasja G. Lieuwes, Linda Spiegelberg, Ala Yaromina, Jean-Yves Winum, Marc Vooijs, Philippe Lambin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Tumour hypoxia and its molecular responses have been shown to be associated with poor prognosis. Detection of hypoxia, preferably in a non-invasive manner, could therefore predict treatment outcome and serve as a tool to individualize treatment. This review gives an overview of recent literature on hypoxia imaging markers currently used in clinical trials. Furthermore, recent progress made in targeting hypoxia (hypoxia-activated prodrugs) or hypoxia response (carbonic anhydrase IX inhibitors) is summarized. Last, window-of-opportunity trials implementing non-invasive imaging are proposed as an important tool to prove anti-tumour efficacy of experimental drugs early during drug development.
Original languageEnglish
Pages (from-to)352-357
JournalRadiotherapy and Oncology
Issue number3
Publication statusPublished - Sept 2015


  • Hypoxia
  • Imaging
  • Carbonic anhydrase IX
  • Therapy
  • Window-of-opportunity trial

Cite this